Adoptive allogeneic immunotherapy--history and future perspectives (Q34062749)

30 July 2017

1 reference

title

Adoptive allogeneic immunotherapy--history and future perspectives (English)

1 reference

30 July 2017

1 reference

Schleuning M

1

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

23

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

133-150

1 reference

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

The occurrence of cancer in immune deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

T cell subsets and graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Adoptive immunotherapy in canine chimeras

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Preclinical large animal models for hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Identical-twin bone marrow transplants for leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Treatment of a patient in a relapse after bone marrow transplantation for acute lymphoblastic leukemia with the systemic administration of allogeneic lymphokine-activated killer cells and recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Graft-versus-myeloma effect in two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

1 reference

7 January 2021

Donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Bcr-abl protein detection in peripheral blood mononuclear cells for follow-up of chronic myelogenous leukaemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

Mini-allografts: ongoing trials in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900078-3

7 January 2021

10.1016/S0955-3886(00)00078-3

Identifiers

DOI

1 reference

30 July 2017

1 reference